The inhibition of LCK by preventing its phosphorylation is an important strategy for the treatment of malignant hematopoiesis such as T-ALL, particularly with the use of bosutinib, dasatinib, or daracatinib, which affect the proliferation of leukemia cells [55,56,57]. This evidence concerns the gene LCK and acute lymphoblastic leukemia.